Profil
Ashutosh Chilkoti was the founder of PhaseBio Pharmaceuticals, Inc., founded in 2002, and held the title of Director from 2011 to 2018.
Dr. Chilkoti is the founder of Isolere Bio, Inc., founded in 2017, and holds the title of Director.
Dr. Chilkoti is the founder of inSoma Bio, Inc., founded in 2018, and holds the title of Chairman.
Dr. Chilkoti currently holds the position of Professor at Duke University.
Postes actifs de Ashutosh Chilkoti
| Sociétés | Poste | Début |
|---|---|---|
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
inSoma Bio, Inc.
inSoma Bio, Inc. Medical SpecialtiesHealth Technology Develops reconstructive plastic surgery products | Fondateur | 01/01/2018 |
Isolere Bio, Inc.
Isolere Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as an early-stage biotechnology company that develops novel and proprietary reagents | Fondateur | 01/01/2017 |
Anciens postes connus de Ashutosh Chilkoti
| Sociétés | Poste | Fin |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Fondateur | 27/08/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Isolere Bio, Inc.
Isolere Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as an early-stage biotechnology company that develops novel and proprietary reagents | Health Technology |
inSoma Bio, Inc.
inSoma Bio, Inc. Medical SpecialtiesHealth Technology Develops reconstructive plastic surgery products | Health Technology |
















